Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection
Chronic Hepatitis C (HCV) infection is an important cause of morbidity and mortality in patients with end-stage renal disease. Renal transplantation confers a survival advantage in HCV-infected patients. Renal transplant candidates with serologic evidence of HCV infection should undergo a liver biop...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.4061/2011/245823 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555811990142976 |
|---|---|
| author | Ignatius Y. S. Tang Natasha Walzer Nidhi Aggarwal Ivo Tzvetanov Scott Cotler Enrico Benedetti |
| author_facet | Ignatius Y. S. Tang Natasha Walzer Nidhi Aggarwal Ivo Tzvetanov Scott Cotler Enrico Benedetti |
| author_sort | Ignatius Y. S. Tang |
| collection | DOAJ |
| description | Chronic Hepatitis C (HCV) infection is an important cause of morbidity and mortality in patients with end-stage renal disease. Renal transplantation confers a survival advantage in HCV-infected patients. Renal transplant candidates with serologic evidence of HCV infection should undergo a liver biopsy to assess for fibrosis and cirrhosis. Patients with Metavir fibrosis score ≤3 and compensated cirrhosis should be evaluated for interferon-based therapy. Achievement of sustained virological response (SVR) may reduce the risks for both posttransplantation hepatic and extrahepatic complications such as de novo or recurrent glomerulonephritis associated with HCV. Patients who cannot achieve SVR and have no live kidney donor may be considered for HCV-positive kidneys. Interferon should be avoided after kidney transplant except for treatment of life-threatening liver injury, such as fibrosing cholestatic hepatitis. Early detection, prevention, and treatment of complications due to chronic HCV infection may improve the outcomes of kidney transplant recipients with chronic HCV infection. |
| format | Article |
| id | doaj-art-ca18f95f3e9f4458b92ed91e6ff9a33e |
| institution | Kabale University |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-ca18f95f3e9f4458b92ed91e6ff9a33e2025-02-03T05:47:13ZengWileyInternational Journal of Nephrology2090-214X2090-21582011-01-01201110.4061/2011/245823245823Management of the Kidney Transplant Patient with Chronic Hepatitis C InfectionIgnatius Y. S. Tang0Natasha Walzer1Nidhi Aggarwal2Ivo Tzvetanov3Scott Cotler4Enrico Benedetti5Section of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USASection of Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USASection of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USADivision of Transplant Surgery, Department of Surgery, University of Illinois at Chicago, Chicago, IL 60612, USASection of Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USADivision of Transplant Surgery, Department of Surgery, University of Illinois at Chicago, Chicago, IL 60612, USAChronic Hepatitis C (HCV) infection is an important cause of morbidity and mortality in patients with end-stage renal disease. Renal transplantation confers a survival advantage in HCV-infected patients. Renal transplant candidates with serologic evidence of HCV infection should undergo a liver biopsy to assess for fibrosis and cirrhosis. Patients with Metavir fibrosis score ≤3 and compensated cirrhosis should be evaluated for interferon-based therapy. Achievement of sustained virological response (SVR) may reduce the risks for both posttransplantation hepatic and extrahepatic complications such as de novo or recurrent glomerulonephritis associated with HCV. Patients who cannot achieve SVR and have no live kidney donor may be considered for HCV-positive kidneys. Interferon should be avoided after kidney transplant except for treatment of life-threatening liver injury, such as fibrosing cholestatic hepatitis. Early detection, prevention, and treatment of complications due to chronic HCV infection may improve the outcomes of kidney transplant recipients with chronic HCV infection.http://dx.doi.org/10.4061/2011/245823 |
| spellingShingle | Ignatius Y. S. Tang Natasha Walzer Nidhi Aggarwal Ivo Tzvetanov Scott Cotler Enrico Benedetti Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection International Journal of Nephrology |
| title | Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection |
| title_full | Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection |
| title_fullStr | Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection |
| title_full_unstemmed | Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection |
| title_short | Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection |
| title_sort | management of the kidney transplant patient with chronic hepatitis c infection |
| url | http://dx.doi.org/10.4061/2011/245823 |
| work_keys_str_mv | AT ignatiusystang managementofthekidneytransplantpatientwithchronichepatitiscinfection AT natashawalzer managementofthekidneytransplantpatientwithchronichepatitiscinfection AT nidhiaggarwal managementofthekidneytransplantpatientwithchronichepatitiscinfection AT ivotzvetanov managementofthekidneytransplantpatientwithchronichepatitiscinfection AT scottcotler managementofthekidneytransplantpatientwithchronichepatitiscinfection AT enricobenedetti managementofthekidneytransplantpatientwithchronichepatitiscinfection |